Reshma Kewalramani Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Reshma Kewalramani.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Reshma Kewalramani. Reshma Kewalramani is CEO & President in VERTEX PHARMACEUTICALS INC / MA ($VRTX) and EVP and CMO in VERTEX PHARMACEUTICALS INC / MA ($VRTX).
Latest Insider Trading Transactions of Reshma Kewalramani
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Payment of Exercise | F | 217.57 | 2,898 | 630,518 | 63,643 | 66.5 K to 63.6 K (-4.36 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Payment of Exercise | F | 211.75 | 2,080 | 440,440 | 66,541 | 68.6 K to 66.5 K (-3.03 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 29,031 | 0 | 71,583 | 42.6 K to 71.6 K (+68.22 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 12,388 | 0 | 42,552 | 30.2 K to 42.6 K (+41.07 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 3,516 | 0 | 30,164 | 26.6 K to 30.2 K (+13.19 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 29,031 | 0 | 71,583 | 42.6 K to 71.6 K (+68.22 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 12,388 | 0 | 42,552 | 30.2 K to 42.6 K (+41.07 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 3,516 | 0 | 30,164 | 26.6 K to 30.2 K (+13.19 %) |
| Aug 10 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Option Exercise | M | 155.57 | 509 | 79,185 | 3,058 | |
| Aug 10 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Option Exercise | M | 187.53 | 1,564 | 293,297 | 15,642 | |
| Aug 10 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 273.27 | 93 | 25,414 | 26,626 | 26.7 K to 26.6 K (-0.35 %) |
| Aug 10 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 272.76 | 487 | 132,834 | 26,719 | 27.2 K to 26.7 K (-1.79 %) |
| Aug 10 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 271.42 | 471 | 127,839 | 27,206 | 27.7 K to 27.2 K (-1.70 %) |
| Aug 10 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 270.36 | 870 | 235,213 | 27,677 | 28.5 K to 27.7 K (-3.05 %) |
| Aug 10 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 269.11 | 152 | 40,905 | 28,547 | 28.7 K to 28.5 K (-0.53 %) |
| Aug 10 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Buy | M | 155.57 | 509 | 79,185 | 28,699 | 28.2 K to 28.7 K (+1.81 %) |
| Aug 10 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Buy | M | 187.53 | 1,564 | 293,297 | 28,190 | 26.6 K to 28.2 K (+5.87 %) |
| May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 288.37 | 9 | 2,595 | 26,626 | 26.6 K to 26.6 K (-0.03 %) |
| May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 287.63 | 19 | 5,465 | 26,635 | 26.7 K to 26.6 K (-0.07 %) |
| May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 286.07 | 27 | 7,724 | 26,654 | 26.7 K to 26.7 K (-0.10 %) |
| May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 283.76 | 10 | 2,838 | 26,681 | 26.7 K to 26.7 K (-0.04 %) |
| May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 282.74 | 4 | 1,131 | 26,691 | 26.7 K to 26.7 K (-0.01 %) |
| May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 281.74 | 6 | 1,690 | 26,695 | 26.7 K to 26.7 K (-0.02 %) |
| May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 280.47 | 9 | 2,524 | 26,701 | 26.7 K to 26.7 K (-0.03 %) |
| May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 279.70 | 7 | 1,958 | 26,710 | 26.7 K to 26.7 K (-0.03 %) |
| May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 276.40 | 6 | 1,658 | 26,717 | 26.7 K to 26.7 K (-0.02 %) |
| May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 274.37 | 2 | 549 | 26,723 | 26.7 K to 26.7 K (-0.01 %) |
| May 08 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Option Exercise | M | 155.57 | 510 | 79,341 | 3,567 | |
| May 08 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Option Exercise | M | 187.53 | 1,564 | 293,297 | 17,206 | |
| May 08 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 275.17 | 134 | 36,873 | 26,626 | 26.8 K to 26.6 K (-0.50 %) |
| May 08 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 274.04 | 864 | 236,771 | 26,760 | 27.6 K to 26.8 K (-3.13 %) |
| May 08 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 272.77 | 360 | 98,197 | 27,624 | 28 K to 27.6 K (-1.29 %) |
| May 08 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 271.92 | 300 | 81,576 | 27,984 | 28.3 K to 28 K (-1.06 %) |
| May 08 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Sell | S | 270.35 | 416 | 112,466 | 28,284 | 28.7 K to 28.3 K (-1.45 %) |
| May 08 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Buy | M | 155.57 | 510 | 79,341 | 28,700 | 28.2 K to 28.7 K (+1.81 %) |
| May 08 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Buy | M | 187.53 | 1,564 | 293,297 | 28,190 | 26.6 K to 28.2 K (+5.87 %) |
| Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 239.13 | 111 | 26,543 | 26,626 | 26.7 K to 26.6 K (-0.42 %) |
| Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 238.28 | 420 | 100,078 | 26,737 | 27.2 K to 26.7 K (-1.55 %) |
| Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 236.71 | 320 | 75,747 | 27,157 | 27.5 K to 27.2 K (-1.16 %) |
| Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 235.36 | 340 | 80,022 | 27,477 | 27.8 K to 27.5 K (-1.22 %) |
| Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 234.41 | 660 | 154,711 | 27,817 | 28.5 K to 27.8 K (-2.32 %) |
| Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 232.35 | 440 | 102,234 | 28,477 | 28.9 K to 28.5 K (-1.52 %) |
| Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 230.88 | 450 | 103,896 | 28,917 | 29.4 K to 28.9 K (-1.53 %) |
| Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 229.72 | 893 | 205,140 | 29,367 | 30.3 K to 29.4 K (-2.95 %) |
| Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Payment of Exercise | F | 239.23 | 2,898 | 693,289 | 30,260 | 33.2 K to 30.3 K (-8.74 %) |
| Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 245.75 | 129 | 31,702 | 33,158 | 33.3 K to 33.2 K (-0.39 %) |
| Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 244.94 | 260 | 63,684 | 33,287 | 33.5 K to 33.3 K (-0.78 %) |
| Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 243.76 | 134 | 32,664 | 33,547 | 33.7 K to 33.5 K (-0.40 %) |
| Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 242.62 | 540 | 131,015 | 33,681 | 34.2 K to 33.7 K (-1.58 %) |
| Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 241.71 | 120 | 29,005 | 34,221 | 34.3 K to 34.2 K (-0.35 %) |
| Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Payment of Exercise | F | 241.50 | 944 | 227,976 | 34,341 | 35.3 K to 34.3 K (-2.68 %) |
| Nov 26 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Option Exercise | M | 187.53 | 4,692 | 879,891 | 20,334 | |
| Nov 26 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 219.37 | 4,692 | 1,029,284 | 13,098 | 17.8 K to 13.1 K (-26.37 %) |
| Nov 26 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Buy | M | 187.53 | 4,692 | 879,891 | 17,790 | 13.1 K to 17.8 K (+35.82 %) |
| Nov 19 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 205.95 | 61 | 12,563 | 13,098 | 13.2 K to 13.1 K (-0.46 %) |
| Nov 13 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Option Exercise | M | 155.57 | 509 | 79,185 | 4,587 | |
| Nov 13 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 199.00 | 509 | 101,291 | 13,098 | 13.6 K to 13.1 K (-3.74 %) |
| Nov 13 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Buy | M | 155.57 | 509 | 79,185 | 13,607 | 13.1 K to 13.6 K (+3.89 %) |
| Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Option Exercise | M | 155.57 | 3,057 | 475,577 | 5,096 | |
| Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Option Exercise | M | 155.57 | 3,057 | 475,577 | 5,096 | |
| Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 199.00 | 3,057 | 608,343 | 13,098 | 16.2 K to 13.1 K (-18.92 %) |
| Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 199.00 | 3,057 | 608,343 | 13,098 | 16.2 K to 13.1 K (-18.92 %) |
| Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Buy | M | 155.57 | 3,057 | 475,577 | 16,155 | 13.1 K to 16.2 K (+23.34 %) |
| Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Buy | M | 155.57 | 3,057 | 475,577 | 16,155 | 13.1 K to 16.2 K (+23.34 %) |
| Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 189.00 | 638 | 120,582 | 13,098 | 13.7 K to 13.1 K (-4.64 %) |
| May 17 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 165.41 | 241 | 39,864 | 13,736 | 14 K to 13.7 K (-1.72 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 188.49 | 100 | 18,849 | 13,736 | 13.8 K to 13.7 K (-0.72 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 187.27 | 202 | 37,829 | 13,836 | 14 K to 13.8 K (-1.44 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 186.75 | 1,186 | 221,486 | 14,038 | 15.2 K to 14 K (-7.79 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Option Exercise | A | 187.53 | 25,026 | 4,693,126 | 25,026 | |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Grant | A | 0.00 | 9,799 | 0 | 15,224 | 5.4 K to 15.2 K (+180.63 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Grant | A | 0.00 | 3,516 | 0 | 5,425 | 1.9 K to 5.4 K (+184.18 %) |
| Oct 09 2018 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 186.95 | 2,305 | 430,920 | 1,909 | 4.2 K to 1.9 K (-54.70 %) |
Page: 1